InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.017 0.005 (41.67%)+
Announcement
Release
29 Apr 2026 9:42AM
Price at Release
$0.012
Full Release
download
Summary
Neurotech International Limited reported its quarterly activities and Appendix 4C cash flow for the period ending 31 March 2026. Key highlights include the initiation of the first clinical site for the Phase 3 'Beyond Harmony' trial for NTI164 targeting Autism Spectrum Disorder (ASD), and the publication of positive results from clinical and mechanistic studies in Neurotherapeutics. The company closed the quarter with cash and cash equivalents of approximately $4.3 million, with total operating cash outflows of about $2.2 million. Neurotech expects significant cash inflows from R&D tax incentives and plans to manage its expenditure accordingly.
Key Points
  • Initiation of Phase 3 'Beyond Harmony' trial for NTI164 in ASD
  • Publication of positive NTI164 clinical results in Neurotherapeutics
  • Quarterly closing cash and equivalents at ~$4.3M
  • Operating cash outflows of ~$2.2M
  • Expected R&D tax incentive inflows of ~$3.5M
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.